This company has been marked as potentially delisted and may not be actively trading. Proteon Therapeutics (PRTO) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock PRTO vs. PLX, IKT, IZTC, CVM, ZIVO, CRTX, JATT, ALVR, FNCH, and AIMShould you be buying Proteon Therapeutics stock or one of its competitors? The main competitors of Proteon Therapeutics include Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), Cortexyme (CRTX), JATT Acquisition (JATT), AlloVir (ALVR), Finch Therapeutics Group (FNCH), and AIM ImmunoTech (AIM). These companies are all part of the "medical" sector. Proteon Therapeutics vs. Its Competitors Protalix BioTherapeutics Inhibikase Therapeutics Invizyne Technologies CEL-SCI ZIVO Bioscience Cortexyme JATT Acquisition AlloVir Finch Therapeutics Group AIM ImmunoTech Proteon Therapeutics (NASDAQ:PRTO) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk. Do institutionals and insiders hold more shares of PRTO or PLX? 23.0% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 45.7% of Proteon Therapeutics shares are held by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, PRTO or PLX? Protalix BioTherapeutics has higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProteon TherapeuticsN/AN/A-$20.73M-$1.15-2.73Protalix BioTherapeutics$61.95M2.33$8.31M$0.0725.86 Is PRTO or PLX more profitable? Proteon Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Proteon Therapeutics' return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Proteon TherapeuticsN/A N/A -118.68% Protalix BioTherapeutics -21.03%-30.89%-11.74% Do analysts recommend PRTO or PLX? Protalix BioTherapeutics has a consensus target price of $15.00, suggesting a potential upside of 728.73%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Proteon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Proteon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, PRTO or PLX? Proteon Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.23, meaning that its share price is 123% less volatile than the S&P 500. Does the media prefer PRTO or PLX? In the previous week, Protalix BioTherapeutics had 1 more articles in the media than Proteon Therapeutics. MarketBeat recorded 1 mentions for Protalix BioTherapeutics and 0 mentions for Proteon Therapeutics. Protalix BioTherapeutics' average media sentiment score of 0.78 beat Proteon Therapeutics' score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Proteon Therapeutics Neutral Protalix BioTherapeutics Positive SummaryProtalix BioTherapeutics beats Proteon Therapeutics on 9 of the 15 factors compared between the two stocks. Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTO vs. The Competition Export to ExcelMetricProteon TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.64M$289.72M$5.84B$10.14BDividend YieldN/AN/A5.68%4.60%P/E Ratio-2.73N/A75.4125.98Price / SalesN/A420.31515.81181.13Price / CashN/A22.4437.5660.44Price / Book-52.3310.9112.156.29Net Income-$20.73M-$111.61M$3.29B$271.07M Proteon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTOProteon TherapeuticsN/A$3.14-1.9%N/A+81.5%$69.64MN/A-2.7317PLXProtalix BioTherapeutics2.3286 of 5 stars$1.72+8.9%$15.00+772.1%+70.8%$137.14M$61.95M-13.23200Positive NewsIKTInhibikase Therapeutics1.4726 of 5 stars$1.67+0.6%$6.50+289.2%+32.2%$123.70MN/A-0.636IZTCInvizyne TechnologiesN/A$12.00+0.3%N/AN/A$75.02MN/A0.0029News CoverageGap UpCVMCEL-SCI1.343 of 5 stars$10.69+3.3%N/A-73.3%$71.23MN/A-22.2743Positive NewsShort Interest ↓ZIVOZIVO Bioscience0.3497 of 5 stars$13.50-9.1%N/A-3.7%$51.53M$15.85K-2.7710News CoverageHigh Trading VolumeCRTXCortexymeN/A$1.57-2.5%N/A+117.7%$47.34MN/A-0.5355JATTJATT AcquisitionN/A$2.21+0.5%N/A-44.4%$38.12MN/A0.003News CoverageHigh Trading VolumeALVRAlloVirN/A$4.64+0.4%N/A-77.5%$23.40MN/A-0.23110Gap DownHigh Trading VolumeFNCHFinch Therapeutics Group1.4043 of 5 stars$12.67-0.2%N/A+9.7%$20.35MN/A-1.44190Negative NewsShort Interest ↓AIMAIM ImmunoTech1.4848 of 5 stars$2.57-0.8%$275.00+10,600.4%-91.2%$7.02M$121K-5.4720Gap Down Related Companies and Tools Related Companies Protalix BioTherapeutics Alternatives Inhibikase Therapeutics Alternatives Invizyne Technologies Alternatives CEL-SCI Alternatives ZIVO Bioscience Alternatives Cortexyme Alternatives JATT Acquisition Alternatives AlloVir Alternatives Finch Therapeutics Group Alternatives AIM ImmunoTech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTO) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
